Another recombinant IL-1 blocker, rilonacept, which functions as an IL-1α and IL-1β trap, has shown beneficial effects on patients with recurrent pericarditis in the phase 3 clinical trial, RHAPSODY [100]. This evidence concerns the gene IL1A and pericarditis.